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ABSTRACT

Spin trapping compositions in general have now been dis
covered to be e?°ective in treating a variety of disorders,
including disorders such as those arising from ischemia,
infection, in?ammation, exposure to radiation or cytotoxic
compounds, not just of the central and peripheral nervous
systems but of peripheral organ disease having a wide

variety of etiologies. In the preferred embodiment, the
compositions for treating tissue damage from ischernia
contain PBN, or active derivatives thereof, in a suitable

pharmaceutical carrier for intravenous, oral, topical, or
nasal/pulmonary administration. Many different disorders
can be treated using these compounds, including diseases or
disorders of the central and peripheral nervous systems, and

disorders arising from ischemia, infection, in?ammation,
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oxidation from exposure to radiation or cytotoxic com
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pounds, as well as due to naturally occurring processes such
as aging.
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SPlN TRAPPING PHARMACEUTICAL
COMPOSITIONS AND METHODS FOR USE

for the generation of oxidized material in the brain. A
marked reduction in certain neurotransmitter receptor sys
tems has been associated with increased oxidation of pro—
teins. For example, decreases in muscarinic receptors and
other cholinergic systems have been characterized as they
relate to alterations in functions in Alzheimers disease. It has

TI-HEREOF
This is a continuation of application Ser. No, 08/052,870
?led on Apr. 26, 1993, (now abandoned) which is a CONT
of Ser. No. 07/716,952, ?led Jun. 18, 1991, (now aban
doned) which is a CIP of Ser. No. 07/589,177, ?led Sep. 27,
1990, (now abandoned) which is a CIP of Ser. No. 07/422,
651, ?led Oct. 17, 1989, now U.S. Pat. 5,025,032.

also been hypothesized that aging is associated with multiple
minor periods of ischemia (multi-infarct conditions or tran~
sient ischemia attacks) which, over a period of time, may

give rise to the production of oxidized protein.
The demonstration in a variety of systems, both neural
and nonneural, that there is an age related enhancement of

BACKGROUND OF THE INVENTION

The present invention is a method and compositions

containing spin trapping agents for the treatment of dys

15

functions and disease conditions arising from oxidative

damage.
As ?rst described in U.S. Pat. Ser. No. 07/422,651 (U.S.

Pat. No. 5,025,032), oxygenated tissue suffers damage, in
many cases permanent damage, if it becomes ischemic and

20

those cells in that particular area of the central nervous

system. The data presented in U.S. Ser. No. 07/589,177 (now
abandoned) was the ?rst report of substantial investigations
in which alterations in the oxidized protein burden of the

is then reperfused. Brain appears to be uniquely susceptible
to ischernia/reperfusion injury. Certain areas of the brain, for
example, the hippocampus and spinal cord, are more sus~
ceptible than other regions of the brain. As a result,
ischemia/reperfusion injury to brain may have a multiplica

central nervous system was manipulated and correlated with
a functional outcome on the part of the animal.
There are a number of other disorders and diseases which

tive e?°ect simply because of the necessity for complete
integrity of all regions in order to have proper functioning.
Free radicals have been postulated to be mediators of

reperfusion damage. The important production sites of such
radicals as the superoxide (.O"2) and hydroxyl (OH——)

the level of oxidized protein in tissue gives rise to the
possibility that age related dysfunctions in the central ner
vous system may be associated with the build-up of oxidized
proteins and oxidized macromolecules within neurons
throughout the central nervous system. The hypothesis is
that cells which have a buildup of oxidized protein are less
functional and less able to maintain the speci?ed role of

have now been postulated to be associated with oxidation of
30

proteins, including many central nervous system (CNS)
diseases besides stroke and aging, including Parkinsonism,
trauma, vascular headaches, and neuroanesthesia adjunct, as

species are the mitochondrial respiratory chain and the

well as peripheral nervous system diseases such as diabetic

sequences catalyzed by cyclooxygenase and lipoxygenase.

peripheral neuropathy and traumatic nerve damage, as well
as peripheral organ diseases. Examples of peripheral organ
diseases include atherosclerosis, pulmonary ?brosis, pancre‘

However, radicals are also formed during autoxidation of

many compounds (e.g., catecholarnines). Several ischemic
events favor a spurt of free-radical formation, such as those

causing oxidation of polyenoic free fatty acids, release and
reuptake of catecholamines, and oxidation of hypoxanthine
by xanthine oxidase. Despite these events occurring during
recirculation, when the O2 supply is restored, they represent
metabolic cascades triggered by agonist-receptor interac

35
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tions, energy failure, and/or calcium in?ux during the insult.
Although free radical formation was‘postulated to be a
likely cause of ischemic damage, it was di?icult to directly

atitis, angioplasty, multiple organ failure, burns, and
ischemic bowel disease.
It is therefore an object of the present invention to provide
spin-trapping composition and methods for use thereof
which are useful in preventing or reversing ischemic damage
in vivo, in the (CNS, resulting from diseases such as stroke,

aging, Parkinsonism, concussion, Berry aneurysm, ventricu
lar hemorrhage and associated vasospasm, ‘spinal cord
trauma, vascular headaches, and neuroanesthesia adjunct.
It is another object of the present invention to provide
spin-trapping compositions, and methods for use thereof,
which are useful in treating damage in vivo resulting from

demonstrate that such formation occurs and/or that it was

su?iciently pronounced to overwhelm the antioxidative
defense of the tissue, as reviewed by Curran, et al., Mol.

Cell. Biol. 5, 167-172 (1985). Phenyl butyl nitrone (PBN)

peripheral nervous system diseases, including diabetic,

has been used in a number of these in vitro research studies

peripheral neuropathy and traumatic nerve damage.
It is still another object of the present invention to provide
spin-trapping compositions, and methods for use thereof,

using spin trapping to look for free radicals, but until
demonstrated by the data in U.S. Ser. No. 07/422,651, (U.S.

50

Pat. No. 5,025,032) there has been no data to support the

which are useful in preventing or reversing free radical

proposition that it could be useful in vivo, particularly with
respect to treatment of tissue damage in the central nervous
system. In vivo, the drug must be able to both cross the blood

55

brain barrier and act in a manner which reduces tissue

damage during or following ischemia.

anti-cancer, pancreatitis, angioplasty, multi-organ failure

In U.S. Ser. No. 07/589,177, (now abandoned) the use of
PBN and related compounds, as well as 5,5-dimethyl pyr

roline N-oxide (DMPO) and ot-(4-pyridy1-1~oxide)-N-tert
butylnitrone (POBN), for treatment of aging was described.
Age related changes in central nervous system function have
generally been associated with the loss of cells, a widening
of lateral ventricles and de?cits in short term memory. The
precise mechanisms of functional changes as a result of
aging, or other diseases associated with aging, have not

generally been agreed upon, including several mechanisms

damage in vivo resulting from injury, infection and in?am
mation, especially peripheral organ diseases such as chronic
obstructive pulmonary disease (COPD), atherosclerosis
(both diabetic and spontaneous), pulmonary ?brosis due to
following trauma, burns, and ischemic bowel disease.

60

It is a further object of the present invention to treat
disorders not associated with oxidation, :such as undesirable
HDL/LDL ratios, as well as the treatment of damage‘arising

from exposure to cytotoxic compounds and radiation.
65

SUMMARY OF THE INVENTION

Spin trapping compositions in general have now been
discovered to be effective in treating a variety of disorders,

5,622,994
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including disorders such as those arising from ischemia,
infection, in?ammation, exposure to radiation or cytotoxic
compounds, not just of the central and peripheral nervous
systems but of peripheral organ disease having a wide

propranalol, desferal, and lazaroids, antiin?ammatories such

dipine, nitrendipine, diltrazam, and ?unarazine, digitalis,
as prednisone, antioxidants such as vitamin E, and neuro

active compounds such as L-DOPA and acetaminophen are
possible, although in some cases spacers will be required
between the spin-trap and the conjugated compound in order
to preserve maximum activity. The essential criteria for the
selection of the spin trap is that it actively trap free radicals
without cytotoxicity, and that in the applications where
access to the CNS is required for e?icacy, that the com
pounds pass through the blood brain barrier.
Many diiferent disorders can be treated using these com
pounds, including diseases or disorders of the central and
peripheral nervous systems, and disorders arising from
ischemia, infection, in?ammation, oxidation from exposure

variety of etiologies. In the preferred embodiment, the
compositions for treating tissue damage from ischernia
contain PBN, or active derivatives thereof, having the fol~
lowing general formula, in a suitable pharmaceutical carrier
for intravenous, oral, topical, or nasal/pulmonary adminis
tration.

’

H

X

O“

\ C:N+/
/

Y

to radiation or cytotoxic compounds, as well as due to

wherein:
X is phenyl or

naturally occurring processes such as aging.
4

(OR)n
20

DETAILED DESCRIPTION OF THE
INVENTION
it has now been discovered that, further to the methods

wherein R is H,
25

using PBN, DMPO, and POBN, and their derivatives for the
treatment and prevention of ischemic damage described and

ll

claimed in U.S. Ser. No. 07/422,651 ?led Oct. 17, 1989
(now U.S. Pat. No. 5,025,032) and U.S. Ser. No. 07/589,177

Z—C—,

?led Sep. 27, 1990, (now abandoned) the teachings of which

0

or Z; or

30
O

are speci?cally incorporated herein, spin-trapping agents are
generally useful in preventing or treating symptoms associ
ated with a very wide range of disorders of the central and
peripheral nervous system, as well as peripheral organ

disfunction and disease, including not just aging, trauma,

—CH=N

ischemia, but disorders as disparate as undesirable ratios of
Y

35

lipoproteins, ulcerative colitis, and damage arising from
exposure to radiation and cytotoxic compounds (chemo

therapeutic compounds, in most instances).

and n is a whole integer from 1 to 5; or

40

As used herein, a free radical scavenger or spin-trap
reagent is a molecule that will form a stable complex with
a free radical. A free radical carbon trap is a molecule in
which the free radical is localized on a carbon atom or a

nitrogen atom. As a result of this chemical bond formation,
the free radical is no longer damaging to the cell.
Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

Useful Spin-Trapping Compounds
OW

POBN and Derivatives Thereof

The preferred spin-trapping compounds are phenyl
N-tert-butylnitrone, also referred to as ot-phenyl t-butyl
50

wherein W is

nitrone (PBN), and derivatives thereof. PBN is the most
preferred compound at this time, having no measurable
effect on normal or uninjured cells, although a number of

derivatives are also useful, including hydroxy derivatives,
especially 2-, 3- or 4-hydroxy PBN and mono-, di- and
55

trihydroxy tert-butyl nitrone; esters, especially esters which
release 2-, 3, or 4-hydroxyphenyl t-butyl nitrone such as the

or Z; and

acetoxy derivative, 2-, 3-, or 4-carboxyphenyl t-butyl

Z is a C1 to C5 straight or branched alkyl group.

Other preferred spin-trapping agents include 5,5-dimethyl
pyrroline N-oxide (DMPO), ot-(4-pyridyl l-oxide)-N-tert
butylnitrone (POBN), and (TEMPO) and spin-trapping

60

derivatives thereof. Examples of useful derivatives of PBN

include imidazole PBN, phenothiazinyl PBN, nitrosoben
zene PBN, 2 methyl-nitrosopropane PBN, halogenated
derivatives, bifunctional derivatives, conjugates, dimers and
cyclodextran polymers of PBN. Conjugates of calcium
channel blockers such as nimodipine, nicardipine, nife

65

nitrone, such as the ethyl derivative, or phenyl hydroxybutyl
nitrone, such as the acetoxy derivative; alkoxyl derivatives,
especially alkoxyl derivatives which release 2-, or 4-hydrox
yphenyl t-butyl nitrone, such as the methyl derivative; and
acetarnide derivatives, especially acetarnide derivatives
which release 2-, or 4 arninophenyl t-butyl nitrone, such as
the acetyl derivative; diphenyl nitrone (PPN) and the analo
gous diphenyl nitrone derivatives. As used herein, “PBN”
refers to both phenyl N-tert-butyl nitrone and derivatives
thereof, unless otherwise stated.

5,622,994
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The general formula for PBN and useful derivatives
thereof is:

and n is a whole integer from 1 to 5; or
0

11
H

\

/

0-

C=N+

/
X

NH-C-Z;

s

Y

Y is a tert»buty1 group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

wherein?

X is phenyl or

OW
(OR)n

;

15

wherein W is
whereln R is H, -

0
[I

20

O

O

O

II

II

II

C—-CH3, NH—C—Z, C—OZ,

Z—C—

or Z; and
or Z; or

Z is a C1 to C5 straight or branched alkyl group.
The formulas for PBN and speci?c derivatives thereof

25
—CH=N

are:

PBN

DERIVATIVES OF PBN

l

_(|:_

0

O-N

1

\\c

O

C==N + c
c

PBN + NTI‘ROSOBENZENE

0

PBN PEN

\/

O

<
.

PE

PBN

'

‘R

PBN

|_

PBN

/\ /\ PBN

PBN PBN

PBN CYCLODEXTRAN POLYMER

NO

5,622,994
-continued

PBN CYCLIZED
PBN DERIVATIVES

R3
WHEREIN R = HALOGEN, METHYL, OR METHOXY

Other spin-trapping agents can also be used, such as 55 by US. Pat. No. 4,224,340 to Campbell, et al., the teachings

5,5-dimethyl pyrroline N-oxide (DMPO), ot-(4-pyridyl
1-oxide)-N-tert-butylnitrone (POBN), N-tert-butyl-ot-(4-nitro-phenyl)nitrone, N-tert-butylot-(2-sulfophenyl)nitrone,

of which are incorporated herein.
DMPO and Derivativ?s Thereof
The general formula for DMPO’ and Speci?c derivatives

3,3,5,5-tetramethyl-l-pyrroline N-oxide, and 2,4,6-tri-tert- 60 are:

butylnitrosobenzene (BNB), and spin-trapping derivatives

thereof. Derivatives are made using standard techniques, for
.

.

example, by subst1tut1on of the methyl groups, for example,

with halogens or sulfur. Many compounds are commercially
available or can be synthesized using methods known to 65
those skilled in the art. q-phenyl-N-phenylnitrone com
pounds for use as topical antiin?ammaton'es are described

D
A

N

B

\l/
0

/

5,622,994
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wherein A and B are independently CH3, CH2 OH,
OW

CHZOW, or
(CW)!

wherein W is —C—CH3,
11 is an integer from 1 to 5

10

wherein W is
or Z; and

S=H, (OR),,, wherein R is H,

or Z; and
Y

Z is a C1 to C 5 straight or branched alkyl group.

n is a whole number from 1 to 4, or

DMPO dimer

Z is a C1 to C5 straight or branched alkyl group.
TEMPO and Derivatives Thereof

2,2,6,6-tetramethyl piperidinooxy (TEMPO) is a nitrox
ide organic free radical trap. The synthesis and chemistry of
nitroxide free radicals is referenced by Galfney, B. J., pp.

l84~238 in Spin Labeling in Pharmacology Berliner, L.v H.,
C

C

O
35

DMPO conjugated to TEMPO

(Academic Press, NY, NY. 1976), the teachings of which are
incorporated herein. TEMPO and several derivatives thereof
can be purchased from Aldrich Chemical Co., as can many
other spin traps such as PBN, DMPO, and POBN and some

of their derivatives.
DERIVATIVES OF TEMPO
0

O

O

PBN conjugated to DMPO

POBN and Derivatives Thereof

45

The general formula for POBN is:

To

c

cc];I

c

c

c N

0

O

As discussed above, the important criteria for these com

pounds is that they must trap free radicals, especially

hydroxy and superoxide radicals, while remaining non-toxic
to normal cells. In those applications where the compound
must reach the brain and other parts of the CNS, the
compound must also be low molecular weight to pass‘
through the blood brain barrier. In some applications, the

0%2
wherein
Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

55

higher molecular weight dimers and polymers of the spin
trap may have advantages.

Conjugates and Polymers of Spin Trapping Compounds
Examples of other useful compounds include conjugates
of spin traps with known biologically active compounds,
including drugs such as antiin?ammatories, neuroactive
compounds, antioxidants, and calcium channel blockers.

Examples include conjugates of acetaminophen, dopamine
(or DOPA), vitamin E, and nifediphenyl:

5,622,994
13

14
-continued

VITAMIN E AND ANALOGUES THEREOF

i‘ ‘F

C=N +

CH3

CH3

CH3
l

0
CH3

\ c—(CH3)3—CH—0

1
HO

CH2/

CH1

CH3
H

C3

‘is

0

CH3

‘a

‘r?

\ C-(cH3)3—CH—o

C: +

|

H0

CH3’

CH2

CH3
CH3
H 0 CH3

|

I

CH3

|

CH3

CH3

|

| /0

C=N—f“(CH2)3—CH—(CH2)s~CH—(CH2)3—$
CH3
CH1

CH3
OH

\CH2
CH3

NIFEDIPHENYL PBN

N03

MeO

' COMe

C

II

I|\I_
C—(|I—
C

Other drugs that can be conjugated to the spin traps
gies, because the fundamental cause of the condition is
include diltrazam, calcium channel blockers such as nicor- 45 oxidation of protein, nucleic acids, or lipids.
dipine, nifedipine and nitrendipine, ?unarazine, digitalis
Disorders are generally divided into disorders of ' the
analogues, propranalol, desferal, and lazaroids. Conjugates
central and peripheral nervous system and disorders of the
with other types of biologically active molecules can also be
peripheral organs.
made, for example, with antibodies or ligands for speci?c
Disorders of the CNS include stroke, aging, Parkin
receptors (such as certain hormones, enzymes, or even 50 sonism, concussion, aneurysm, ventricular hemorrhage and
speci?c sugars or carbohydrates) which are used to “target”
associated vasospasm, migraine and other vascular head

or otherwise concentrate the spin trapping compound.

aches, spinal cord trauma, and neuroanesthesia adjunct.

Depending on the structure of the spin trap, as well as the

Disorders of the peripheral nervous system include diabetic

biologically active compound, it may be necessary to insert
peripheral neuropathy and traumatic nerve damage.
a spacer between the spin trap and the biologically active 55
Peripheral organ disease includes atherosclerosis (both
compound.
diabetic and spontaneous), chronic obstructive pulmonary
Indications that the compositions are useful in treating.
disease (COPD), pancreatitis, pulmonary ?brosis due to
The spin trap or free-radical scavenger compositions are
chemotherapeutic agents, angioplasty, trauma, burns,
useful in treating a variety of dysfunctions or disorders
ischemic bowel disease, wounds, ulcers and bed sores,
characterized by oxidized proteins or lipids in the tissues, 60 lupus, ulcerative colitis, organ transplantation, renal hyper
cells, or associated ?uids (such as the blood). Oxidation of
tertsion, overexertion of skeletal muscle, and epistaxis (pul
cytosolic protein has been demonstrated to occur in a wide

monary bleeding).

variety of pathological conditions. Accordingly, compounds

Other conditions associated: with excessive oxidation of

which have as their fundamental mechanism of action the

proteins or lipids that can be treated include undesirable or

interference of production of oxidized protein should be 65 altered oxidation of low density lipoprotein, and dysfunction
useful in the treatment of a wide variety of diseases having
from exposure to radiation, including x-ray, ultraviolet,
what appears at ?rst glance to be widely dissimilar etiolo
gamma and beta radiation, and cytotoxic compounds,

5,622,994
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including those used for chemotherapy for cancer and viral
infections.
Treatment of Central Nervous System Diseases
Stroke.
Multiple in vitro studies, as well as the in vivo data
presented in U.S. Ser. No. 07/589,177 (now abandoned) and
U.S. Ser. No. 07/422,651 (U.S. Pat. No. 5,025,032) have
demonstrated that there are a series of biochemical changes

that result in the production of free radicals following
ischernia. PBN and other spin-trapping compounds can
covalently bind to these radicals and prevent the perioxida
tion of cellular proteins and fatty acids. The consequence of
the trapping of these carbon-centered and oxygen-centered
radicals is the termination of the propagation phase of free
radical production within the neuron. This interruption of

Berry Aneurysm and other types of Aneurysm.
This vascular problem results in bleeding on the brain and
presents as a serious and chronic headache or other neuro

logic symptom. The condition is ultimately treated 'by sur
gical repair of the vessel that has developed a weak wall.
However, this condition oftert results in hemorrhage and
neural damage due to the bleeding. In addition, the presence
of blood on the outside of the vessel sensitizes the vessels to
spasm and increases the risk of a stroke, as is also true in
10 concussion and other traumatic conditions. In addition to the

radicals generated by spasm and stroke, the iron or other
metal catalyzed generation of oxygen free radicals, similar
to what has been proposed for ischernia and concussion, also
represents a second source of free radicals.

Ventricular Hemorrhage and Associated Vasospasm.

free radical production can decrease the mortality and mor
bidity seen in strokes.

The same biochemical and physiological conditions as

described for Berry Aneurysm and their management by
spin trapping compounds will apply for these conditions.

Aging
Aging has been demonstrated to be associated with the

production of abnormally high levels of oxidized proteins.

20

The consequence of this increased level of protein oxidation
is an abnormally low level of critical enzymes in the affected
cells. While not all cells have been evaluated, it appears
from the in vivo data presented in U.S. Ser. No. 07/589,177

(now abandoned) and U.S. Ser. No. 07/422,65l, (U.S. Pat.

is another form of ischemia/reperfusion injury. While spin
25

trapping compounds will not prevent the initial occurrence
of these vascular headaches, they should limit the extertt or

frequency by trapping the free radicals that are generated
during the ischernia phase.
Spinal Cord Trauma.

No. 5,225,032) and reports of in vitro studies, that most, if

not all, cells in the body will undergo abnormally high levels
of protein oxidation. Decreases in antioxidant systems and
abnormally low levels of mitochondrial function have been
described. The protein oxidation is thought to arise from
oxygen free radicals, largely generated via a metal catalyzed

Migraine and other Vascular Headaches
Migraines are thought to arise in part from vasodilation
and compression of the microcirculation of the cortex. This

30

Spinal cord trauma involves the interruption of the normal
vascular supply due to shearing forces at the time of the
initial trauma and as a result of the subsequent edema of the

reaction within the cell. Studies have now been conducted

tissue. In addition, the hemorrhage that oftert accompanies

that daily administration of a free radical spin trapping
compound, PBN, for fourteen days completely reverses this
process. Not only is the level of protein oxidation decreased,
but the abnonnally low level of enzyme activity is restored

generated oxygen free radicals. Spin trapping compounds

to normal.

such trauma will also generate vasospasm and directly
35

should limit this process and terminate the intracellular

cascade of lipid and protein oxidation.

-

Neuroanesthesia Adjunct.

Parkinsonism

Several procedures involve resection of brain tissue which
will result in hemorrhage in the immediate area. Other

Research has indicated that one of the principle sources of

doparninergic damage to the striatum is via free radical

surgical procedures may be associated with increased riskof

mediated oxidation. Dopamine can be oxidized to the neu
rotoxin 6-OH dopamine within the neuron. This neurotoxin

cerebral blood flow interruption, either as a natural conse

quence of the procedure, e.g., cardiac surgery or heart

is activated by a second oxidation. Both of these reactions

transplantation, or due to the unexpected interruption of

are thought to occur as a result of oxygen free radical

production and attack on the dopamine, a naturally occur 45 ?ow, e.g., hemorrhage, clot following angioplasty, cardiac

arrest during surgery. In all of these conditions, spin-trap
ping compounds will limit free radical mediated damage.

ring neurotransmitter. These oxygen radical mediated oxi
dations are thought to occur at a relatively slow rate and to

Peripheral Nervous System Diseases

be responsible ‘for the progressive loss of motor function in

Parkinsonism and related conditions. Based upon the dem
Diabetics are well known for their tertdencies to develop
onstration that chronic administration of PBN can decrease 50
peripheral neuropathies and progressively loose sensation in
the progressive oxidation that occurs following a stroke, it is
limbs. In addition, diabetics have a higher risk to develop
believed that PBN and other spin-trapping compounds will
atherosclerosis, which may alfect microvascular function.
be effective in limiting the production of the neurotoxic
One of the most frequently seen biochemical consequences
dopamine oxidation products.
55

Concussion.

The majority of the research literature indicates that
concussion produces the bulk of its long term effects via
interruption of brain and spinal cord microcirculation, pro
ducing localized ischernia. This interruption in blood ?ow

60

can be the result of the initial trauma and shearing of

capillaries or the consequence of the brain edema and
compression of the blood vessels. In any event, spin trapping
compounds should be of therapeutic value as they have been
demonstrated to be in models of stroke.
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of diabetes is excessive glycation of proteins. Following

glycation, there is a burst of protein oxidation that is
mediated by oxygen free radicals. It is though that this
process of excessive glycation is critical in the development
of damage to neurons and axons in the diabetic. Since spin

trapping compounds are quite eifective in limiting intracel
lular free radical mediated damage, such compounds should
be useful in the chronic management of diabetic neuropa—
thies and other long term adverse consequences of diabetes.
Traumatic Nerve Damage.
Crushing injury to peripheral nerves, as in the hands,
arms, and legs, involves interruption of blood ?ow
(ischemia) and edema. Effective and prompt repair is depen
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Angioplasty.

dent on the re-establishment of an effective oxygen and

nutrient supply. Oftert recovering tissue tertds to outgrow its
blood supply and is restricted in recovery by the ischemia

In the process of re~expanding or laser removal of
atheroma, there are periods of ischemia and reperfusion of
the vessel. Recent studies have demonstrated that during this
period, superoxide and nitric oxide are produced. These
products have been demonstrated to further damage the

that occurs as the tissue outgrows the vascular supply.

Spin-trapping compounds should provide greater tolerance
of partial hypoxia as vascular supply grows to reach the

healing tissue. In addition, the same ischemia/hypoxia pro

endothelium and may also remove or damage the natural.
relaxant systems that locally control the vascular tone. If
uncontrolled, such changes are likely to result in an
increased risk of re-occlusion of the same vessel. Spin
trapping compounds can prevent the generation of the
oXy-radical cascade and thereby reduce the likelihood of

tection that occurs in the non-vascular tissue may also
enhance the growth of the endothelia as the revasculariza
tion process occurs.

Peripheral Organ Diseases

reocclusion following angioplasty.
Multi-organ Failure Following Trauma.

Atherosclerosis (Both Diabetic and Spontaneous).
Diabetic atherosclerosis involves the abnormal and exces~ 15

sive glycation of protein in the vascular wall. As discussed
above for diabetic neuropathy, this involves oxygen radical
production and consequent further damage to cytosolic

A characteristic problem following extreme trauma is the

development in the patient of a negative nitrogen balance,

poor protein synthetic capacity, pulmonary dysfunction, and
abnormal cytokine production. Tumor necrosis factor (TNF)
is excessively elevated during this process. TNF is associ
ated with the cellular generation of oxygen free radicals in

proteins. Spin-trapping compounds will prevent this abnor
mal processing of cellular protein and other cellular con
stituents. In vitro studies have been conducted that demon- ‘

tissue and may be one of the primary causes of this condi

strate that PBN inhibits or reduces oxidation of low density

tion. The activation of macrophages and lymphocytes also
plays a critical role in the condition- Free radical production
by the white cells is part of the process of multiple organ

lipoprotein in plasma. Plasma samples were tested for oxi~
dation of lipid measured using thiobarbioturic acid reactive
substance (TBAR, nM) and % inhibition of oxidation calcu

‘damage. Spin-trapping compounds can prevent the propa
gation phase of this condition and limit the extent of
cachexia and organ damage following severe trauma.

lated. Phosphate bu?ered saline (PBS) was added to con
trols, 0.1 mM PBN was added to test samples, and the
controls and sealed samples incubated at 4° C. for seven
weeks.

Diabetic Retinopathy.
Diabetes is a disease of abnormal glycation and partial
ischemia. Both conditions promote free radical production.
The relatively common condition of diabetic retinopathy is

The results are shown in Table I.

TABLE 1
Testing of antioxidation activity of PBN.
35

sample

control + PBS

Test (nM/ml)

% inhibition*

NP132 plasma
NP134 plasma
NP135 plasma

0.55
0.18
0.32

0.45
0.14
0.25

18.2
22.2
21.9

NP133 LDL
NP135 LDL

0.54
0.33

0.23
0.11

48.1
66.7

thought to involve a microvascular and protein dysfunction
of the retina. Spin-trapping compounds can limit the glyca
tion mediated production of free radicals and the~damage

caused by rnicrovascular interruptions.
Burn Treatment and Healing.
Healing from serious bums is limited by the inability of
the repairing vascular system to supply the rapidly growing
40

cutaneum. Periods of ischemia in the dermis will occur as

the growing skin cannot be adequately supplied. This
*The actual percent inhibition in the presence of PBN is greater than the
measured value due to interference in the assay by the PBN.

hypoxia or ischemia results in the production of oxygen free
radicals and either limits the rate of recovery and/or pro~
motes the generation of scar tissue. Systemic and topical

Chronic Obstructive Pulmonary Disease (COPD).

spin-trapping compounds should improve the rate of healing

COPD has been demonstrated to involve the attack of
interstitial alveolar macrophages on pulmonary tissue. Ani
mals models of this clinical condition have demonstrated
that increases or decreases in superoxide dismutase activity
in the lung can result in decreases or increases in pulmonary

and decrease scar formation.

Ischernic Bowel Disease
strangulation of the bowel is a condition that is frequently
50 fatal in both humans and animals such as dogs, horses and
pathology, respectively. An alternative approach is to pro
cattle. Even after resection and anastomosis of the intestine,

vide to the pulmonary tissue, either via the pulmonary
vascular supply or via the airway, radical spin-trapping
compounds which will limit the peroxidation of pulmonary
tissue and the consequent loss of alveolar tissue.
Pancreatitis.
Pancreatitis is believed to be the result of ischernic or

the prognosis is not good. The generation of ischemia
derived oxygen radicals and damage to the intestine is
considered to the be primary cause. There is no effective
treatment
to date.
55

Studies have demonstrated that ischemia induced intesti
nal edema can be prevented or reduced by a number of

chemically derived peroxidation of pancreatic parenchyma.

different spin-trapping compounds.

Alcoholic pancreatitis is probably due to the direct effects of
the ethanol radical and the indirect vascular effects of

equine gastrointestinal disorders and gram negative bacterial

Endotoxin is a primary factor in the pathophysiology of

acetaldehyde mediated direct damage to proteins and indi

infections. The pathophysiological is similar to that charac

rect damage via catecholamine release and mitochondrial
metabolism. There is currently no treatment for acute pan
creatitis. If the condition does not abate, it is generally
regarded as fatal in the severe form. Spin -trapping agents
may mediate the acute reaction, allowing the patient time to

terizing colitis, salmonellosis, and neonatal septicemia. It is
hypothesized that endotoxin produces its toxic effects by
triggering “oxidative bursts” from sensitized macrophages.

recover.

65

These bursts of OZ radicals are intertded to kill invading
bacteria associated with the presence of endotoxin. How
ever, they have the adverse eifect of damaging the tissues in
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which they are produced and this tissue damage is presum
ably the molecular basis of the pathological changes asso
ciated with endotoxin shock. Spin-trapping compounds have
the ability to trap radicals and alleviate many of the toxic
effects associated with radical formation. Additionally,
recent experiments demonstrate that spin trap molecules
protect rats against endotoxin administration.
Wound and Ulcer Healing.
Tissue healing oftert involves periods of hypoxia or
ischemia as the recovering tissue outgrows the vascular

Organ preservation solutions are designed to prepare ‘the
organ to be transplanted for the period of extracorporeal
storage. The most recently developed solution contains
glutathione as an antioxidant. Spin-trapping compounds
differ from glutathione in that they can function both as
antioxidants, trapping oxygen free radicals, as well as trap
ping compounds for both intracellular and extracellular
carbon-centered free radicals.
It is believed organ survival would therefore be enhanced

by administering spin-trapping compounds to the recipient,

supply. Spin-trapping compounds can decrease the damage
associated with this period of ischemia.

as well as adding the compounds to the organ preservation
solution.

Infections as consequence of the development of decubi
tus ulcers is the number one cause of death in the elderly.

The general clinical impression is that elderly patients are
much more likely to develop these ulcers, compared to

Ionizing Radiation Prophylaxis.
15

Ultraviolet radiation acts similarly. The cascade that follows
is functionally identical to the process of cellular damage

interruption of blood ?ow to the skin. This process is
identical to the process of ischemia/reperfusion oxidation of
brain and other tissues. In the geriatric patient, pressure
sores may rapidly develop due to the enhanced oxidation of
cells in the skin. Based upon the observations that spin

caused by ischemia/reperfusion injury to tissue. By selec
tively treating with spin-trapping compounds those tissues

trapping compounds can prevent ischemia/reperfusion
injury to both brain and intestine, it is expected that spin
trapping compounds will reduce or prevent pressure sores.
25

from low renal artery ?ow and high renin.
Renal hypertertsion develops as a result of reduced blood
?ow to the kidney. The juxtaglomerular apparatus (JGA)
recognizes this hypoperfusion and releases renin, which
results in an angiotertsin H mediated increase in blood
pressure (hypertertsion). Hypoperfusion (hypoxia) is a con
dition that is known to result in signi?cant oxygen free

cutaneous toxicities as a result of hydroxyl free radical

production. Adriamycin produces cardiac and gastrointesti'
nal side~effects. The spin-trapping compound PBN has been
demonstrated to trap the free radicals produced by adriamy
cin in heart, brain and other organs of research animals,

radical production, making it probable that oxygen free
radicals are likely to be involved in the release of renin by

the JGA, and therefore manageable at least in part through

using the spin-trapping compound PBN. These spin-trap

administration of spin-trapping compounds.

ping compounds should be useful in limiting side effects in

Exertional Injury to skeletal muscle.

tissues, such as the brain, that the especially vulnerable to

Sore muscles as a result of exercise are thought to be a

develop free radicals without compromising the therapeutic
value of the chemotherapeutic‘agent.
Skin, Muscle Flap and Organ Survival Following Trans

consequence of free radical mediated perioxidation of skel
etal muscle proteins and lipids. Since chronic treatment with
45

Autologous (self) transplantation of skeletal muscles from
area to the other should not involve any immunologic

incompatibilities. However, estimates from surgeons sug
50

rate. It is postulated much of the problem arises a result of

ischemia and reperfusion during the surgical procedures for
55

equally effective in limiting the damage undergone by these
tissues, as well as other organs, during surgery associated

daily treatment with a spin-trapping agent such as PBN.

body. Previous work has demonstrated that chronic admin
istration of the spin-trapping compound PBN can return
cells to the status of a young adult, spin-trapping compounds
should be effective in improving the functional status and
exercise condition of skeletal muscle in aged individuals.

Epistaxis (Pulmonary Bleeding in Horses) and Laminitis
Epistaxis (ES) and laminitis are both thought to involve
ischemia/reperfusion injury to the alveolar basement mem'

brane and the lamina propria of the hoof, respectively. Since
both of these conditions involve the process of reperfusion

with transplantation.
Organs for transplantation are obtained from donors. The
success of the procedure is determined in part by the age
(oxidation) related reduction in organ viability, the amount
of time the organ is in preservation solution and the status of
the recipient. Previous research has demonstrated that spin
trapping compounds can improve the enzymatic status of the
aged brain, restoring enzymatic levels to near those of the
young adult as early as seven days following initiation of

spin-trapping compounds decreases cellular oxidations and
protects enzymes from oxidative inactivation, daily treat
ment should improve the process of exercise conditioning
(especially in the horse). Moreover, aged skeletal muscle is
likely to contain constituents, as do most other cells in the

gest that the success rate is more in the area of 50% success.

removal and implantation. Following ischemia these tissues
undergo calcium loading and eventually necrosis, as in
strokes. Spin-trapping compounds should therefore be

,

Treatment of Renal Hypertertsion Disorders, resulting

compounds are also the result of oxygen free radical pro

Acceptance of skin ?ap grafts has an equally low success

that are not involved by the cancer, it should be possible to
improve the effectiveness and decrease the side effects of
radiation therapies. In the case of environmental exposures,
spin-trapping compounds‘ should be effective both as ea
prophylaxis, applied topically or systemically, as well as a
post-exposure therapeutic.

duct'ion in normal cells. Bleomycin produces pulmonary and

plantation.

environmental toxicant causes its effects by producing

hydroxyl free radicals intracellularly and extracellularly.

young adults. Pressure sores develop as a result of the

In addition, these compounds should be useful systemically
or topically in enhancing recovery.
Reduction in Side-effects of Cancer Chemotherapy.
A number of cancer chemotherapeutic agents produce
their cytotoxic effects via the production of oxygen free
radicals within the cell. The limiting side effects of these,

Ionizing radiation as a therapeutic modality and as an
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generation of free radicals, spin-trapping compounds should
be e?ective in the prevention, management of treatment of
these conditions.

Pharmaceutical Compositions
The spin trapping compounds are administered topically,
65

locally, or systemically, depending on the application. When

administered systemically, the compound is preferably
administered orally or intravenously, in an appropriate phar
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maceutical carrier such as saline or phosphate buffered

ing agents can be included as part of the composition. The
tablets or capsules may contain, for example, any of the
following ingredients, or compounds of a similar nature: a
binder such as microcrystalline cellulose, gum tragacanth or
gelatin; an excipient such as starch or lactose, a disintegrat
ing agent such as alginic acid, Primogel®, or corn starch; a
lubricant such as magnesium stearate or Sterotes; a glidant

saline (PBS) or in tablet form. For topical application, the
compound is preferably administered in an ointment or
cream base, or by means of a transdermal patch. The

compound can also be administered by controlled delivery
devices, such as biodegradable polymers, or by inhalation,
insu?lation or nasal spray. Suitable carriers are known to

those skilled in the pharmaceutical area.

such as colloidal silicon dioxide; a sweeterting agent such as

Effective dosages of Spin Trapping Compounds
Exemplary dosages of PBN administered intravenously

sucrose or saccharin; or a ?avoring agent such as pepper

mint, methyl salicylate, or orange ?avoring. When the
dosage unit form is a capsule, it can contain, in addition to
material of the above type, a liquid. carrier. In addition,
dosage unit forms can contain various other materials which

range from 0.1 to 10 mg/kg of body weight in animals. The
effective dosage of PBN in humans for treating age and
ischemic related disorders is expected to be between

modify the physical form of the dosage unit, for example,

approximately 1 and 10 mg/70 kg body weight. Toxicity

coatings of sugar, shellac, or other enteric agents.
Modi?cations and variations of the spin trapping compo
sitions for the treatment of a variety of disorders associated
with oxidation of proteins and/or lipids will be obvious to
those skilled in the art from the foregoing detailed descrip

tests have demonstrated that the compound is completely
innocuous, with such low toxicity that it was not possible to
determine an LDSQ. It is possible to extrapolate from com
- parative tests using other spin trapping compounds what the

elfective dosage for these compounds will be.
Since the trapping of endogenous free radicals is speci?c

20 tion. Such modi?cations and variations are intertded to come

within the scope of the appended claims.
We claim:
1. A method for ameliorating the side e?cects caused in a

for only those cells that have been exposed to the conditions
that result in the production of free radicals, the traps have
little or no effect on normal cells. The bene?cial effects

patient by oxidative damage resulting from the administra

occur only in injured cells, and do not require the presence

tion to said patient of a cancer therapeutic agent, said

of speci?c receptors, speci?c enzymes, and/or speci?c cell
types.

method comprising administering to said patient an effective
side effect-ameliorating amount of an active ingredient
selected from the group consisting of:

Methods of administration of PBN.

The spin trapping compound is preferably administered
systemically, most preferably intravenously or orally, since
these are the most rapid and ef?cient means for delivering
the active compound to the site of free radical generation.

The spin trapping compound may be administered at once,
or may be divided into a number of smaller doses to be

administered at varying intervals of time. Other methods of
systemic administration can also be used, including inhala
tion or insu?lation, subcutaneous, intravenous, and intrap
eritoneal administration. The spin trapping compound can

35

also be administered topically, in an ointment, creme, or

transdermal patch. The concentration of active compound in
the drug composition will depend on absorption, inactiva

40

tion, and excretion rates of the drug as well as other factors
known to those skilled in the art. It is to be noted that dosage

values will also vary with the condition of the patient being
treated. It is to be further understood that for any particular

(l) phenyl N-tert-butyl nitrone (PBN) derivatives selected
from the group consisting of hydroxy PBNs, PBN
esters, acetoxy PBNs, phenyl PBNs, alkyl PBNs,
alkoxy PBNs, acetamide PBNs, and diphenyl PBNs;
(2) imidazole PBN, phenothiazinyl PBN, nitrosobenzene
PBN, 2-methyl nitrosopropane PBN, PBN Cyclodext
ran polymer and cyclized PBN;
(3) 5,5-dimethyl pyrroline N-oxide (DMPO) esters,
acetoxy DMPOs, phenyl DMPOs, alkyl DMPOs, aceta
mide DMPOs, diphenyl DMPOs, and DMPO dimers;

(4) alpha-(4-pyridyl 1-oxide)~N-tert-butylnitrone (POBN)
esters, hydroxy POBNs, phenyl POBNs, alkoxy
POBNs, and acetamide POBNs;
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subject, speci?c dosage regimens should be adjusted over
time according to the individual need and the professional
judgment of the person administering or supervising the
administration of the compositions, and that the concentra
tion ranges set forth herein are exemplary only and are not

intertded to limit the scope or practice of the claimed

composition.
A preferred mode of administration of the active com»
pound is in a form for oral delivery. Oral compositions will

(5) N-tert-butyl-alpha-(4-nitro-phenyl)nitrone;
(6) N-tert-butyl-alpha-(2-sulfophenyl)nitrone;
(7) 3,3,5,5-tetramethyl-1-pyrroline N-oxide;
(8) 2,4,o-tri-tert-butylnitrosobenzene (BNB); and

(9) 2,2,6,6-tetrarnethyl piperidinooxy (TEMPO),
optionally in association with a pharrnaceutically accept
able carrier.
2. The method of claim 1 wherein said cancer therapeutic
agent is selected from the group consisting of bleomycin and

adriamycin.
3. The method of claim 1 wherein said active ingredient

generally include an inert diluent or an edible carrier. 55 is a PBN derivative selected from the group consisting of

Preferred pharmaceutical carriers for intravenous adminis
tration are saline or phosphate bu?ered saline at physiologi

cal pH. Since some compounds are pH sensitive, stability of
the compound in the carrier should be determined and the
pH of the carrier adjusted appropriately, or the compound
administered in combination with food, a buffering agent, or
in an enteric coating. For oral delivery, the spin trapping

compound may be enclosed in capsules, compressed into
tablets, nricroencapsulated, entrapped in liposomes, in solu
tion or suspension,alone or in combination with a substrate 65

immobilizing material such as starch or poorly absorbable

salts such as immodium. Phannaceutically compatible bind

hydroxy PBNs, PBN esters, acetoxy PBNs, phenyl PBNs,
alkyl PBNs, alkoxy PBNs, acetamide PBNs, and diphenyl
PBNs.

4. The method of claim 1 wherein said active ingredient
is a PBN derivative selected from the group consisting of

imidazole PBN, phenothiazinyl PBN, nitrosobenzene PBN
and 2-methyl nitrosopropane PBN.
5. The method of claim 1 wherein said active ingredient
is selected from the group consisting of DMPO derivatives
selected from the group consisting of DMPO esters, acetoxy

DMPOs, phenyl DMPOs, alkyl DMPOs, acetamide
DMPOs, diphenyl DMPOs, and DMPO dimers.
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6. The method of claim 1 wherein said active ingredient
is selected from the group consisting of POBN derivatives
selected from the group consisting of POBN esters, hydroxy

11. The method of claim 8 wherein X is
(ORH)

POBNs, phenyl POBNs, alkoxy POBNs, and acetamide
POBNs.
5
7. The method of claim 1 wherein said active ingredient
is administered in association with a pharrnaceutically
12. The method of claim 8 wherein Y is a tert~butyl group.
13. The method of claim 9 wherein Y is a tert-butyl group.
14. The method of claim 8 wherein Y is phenyl.
15. The method of claim 8 wherein Y is

acceptable carrier.
8. A method for ameliorating the side e?ects caused in a

patient by oxidative damage resulting from the administra
tion to said patient of a cancer therapeutic agent, said

method comprising administering to said patient an eifective
side-e?ect ameliorating amount of an active ingredient
de?ned by the formula:
H

X

0

OW

(I)

16. The method of claim 8 wherein Z is C1 to C5 straight

/

chain alkyl.

Y

wherein:
X is phenyl or

20

17. The method of claim 8 wherein said active ingredient
is administered in association with a pharrnaceutically

acceptable canier.
18. A method for ameliorating the side eifects caused in

a patient by oxidative damage resulting from the adminis

(0K)»

tration to said patient of a cancer therapeutic agent, said
25

method comprising administering to said patient an effective
side e?°ect-ameliorating amount of an active ingredient
de?ned by the formula:

wherein R is H,
O

O

and n is a whole integer from l to 5; or

30
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wherein A and B are independently CH2OH, CHZOW, or

s

n is an integer from 1 to 5,

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or

wherein W is

OW

45

or Z; and

wherein W is

50

0

0

II

II

II

Z is a C1 to C5 straight or branched alkyl group, optionally
in association with a pharmaceutically acceptable car
rier.
19. The method of claim 18 wherein A and B are inde-,

c-cm, NH-C-Z, c—oz,

pendently selected from the group consisting of CHZOH and
or Z; and

Z is a C1 to C5 straight or branched alkyl group,
excluding compounds of formula (I) wherein Y is a
tert-butyl group when X is phenyl, optionally in asso~
ciation with a pharrnaceutically acceptable carrier.
9. The method of claim 8 wherein X is

55

CHZOW.
20. The method of claim 18 wherein at least one of A and
B is

21. The method of claim 18 wherein said active ingredient
is administered in association with a pharrnaceutically

acceptable carrier.
22. A method for ameliorating the side e?’ects caused in
10. The method of claim 8 wherein Z is methyl.

a patient by oxidative damage resulting from the adminis
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tration to said patient of a cancer therapeutic agent, said
method comprising administering to said patient an eifective
side effect-ameliorating amount of an active ingredient

-

Z is a C1 to C5 straight or branched alkyl group, optionally
in association with a pharmaceutically acceptable car
r1er.

de?ned by the formula:

23. The method of claim 22 wherein Y is a tert-butyl
group.
24. The method of claim 22 wherein Y is phenyl.
25. The method of claim 22 wherein Y is
OW

i

26. The method of claim 22 wherein S is OH.
27. The method of claim 22 wherein Z is a C1 to C5

straight alkyl group.

wherein

28. The method of claim 22 wherein S is

Y is a tert-butyl group that can be hydroxylated or
acetylated on one or more positions; phenyl; or
20
OW

29. The method of claim 22 wherein S is

1

wherein W is
O

O

0

II

II

II
30. The method of claim 22 wherein S is a C1 to C5
straight or branched alkyl group.
31. The method of claim 22 wherein said active ingredient
is administered in association with a pharmaceutically

NH—-C—Z, —C——CH3, -—C—OZ,
or Z; and

S is (0K)", wherein R is H,

i’

acceptable cairier.

°‘

32. The method of claim 1 wherein the active ingredient

is N-tert-butyl-alpha-(4-nitrogphenyl) nitrone.

Z—C—, Z, or —Cl-l=N+

33. The method of claim 1 wherein the active ingredient
Y

is N~tert-butyl-a1pha-(2-sulfophenyl) nitrone.
34. The method of claim 1 wherein the active ingredient

n is a whole number from 1 to 4, or

is 3,3,5,5-tetramethyl-l-pyrroline N-oxide.
35. The method of claim 1 wherein the active ingredient
is 2,4,6-t1i-tert-butylnitrosobenzene.

.

36. The method of claim 1 wherein the active ingredient
45

and

is 2,2,6,6-tetramethyl piperidinooxy.
*****

